RU2666219C2 - Применение антагониста рецептора NK-1 серлопитанта при зуде - Google Patents

Применение антагониста рецептора NK-1 серлопитанта при зуде Download PDF

Info

Publication number
RU2666219C2
RU2666219C2 RU2015154037A RU2015154037A RU2666219C2 RU 2666219 C2 RU2666219 C2 RU 2666219C2 RU 2015154037 A RU2015154037 A RU 2015154037A RU 2015154037 A RU2015154037 A RU 2015154037A RU 2666219 C2 RU2666219 C2 RU 2666219C2
Authority
RU
Russia
Prior art keywords
administered
therapeutically effective
cream
once
ointment
Prior art date
Application number
RU2015154037A
Other languages
English (en)
Russian (ru)
Other versions
RU2015154037A (ru
Inventor
Сяомин Чжан
Эдвард Ф. ШНИППЕР
Эндрю Дж. ПЕРЛМАН
Джеймс У. ЛАРРИК
Original Assignee
Менло Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/925,509 external-priority patent/US8906951B1/en
Application filed by Менло Терапьютикс Инк. filed Critical Менло Терапьютикс Инк.
Publication of RU2015154037A publication Critical patent/RU2015154037A/ru
Application granted granted Critical
Publication of RU2666219C2 publication Critical patent/RU2666219C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2015154037A 2013-06-24 2014-06-24 Применение антагониста рецептора NK-1 серлопитанта при зуде RU2666219C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361838784P 2013-06-24 2013-06-24
US13/925,509 2013-06-24
US61/838,784 2013-06-24
US13/925,509 US8906951B1 (en) 2013-06-24 2013-06-24 Use of NK-1 receptor antagonists in pruritus
PCT/US2014/043811 WO2014209962A1 (en) 2013-06-24 2014-06-24 Use of nk-1 receptor antagonist serlopitant in pruritus

Publications (2)

Publication Number Publication Date
RU2015154037A RU2015154037A (ru) 2017-07-28
RU2666219C2 true RU2666219C2 (ru) 2018-09-06

Family

ID=51230173

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015154037A RU2666219C2 (ru) 2013-06-24 2014-06-24 Применение антагониста рецептора NK-1 серлопитанта при зуде

Country Status (13)

Country Link
EP (1) EP3013336A1 (enExample)
JP (2) JP2016523260A (enExample)
KR (1) KR20160023692A (enExample)
CN (1) CN105473138A (enExample)
AU (2) AU2014302694B2 (enExample)
BR (1) BR112015031724A2 (enExample)
CA (1) CA2915474A1 (enExample)
HK (1) HK1223820A1 (enExample)
IL (1) IL243189A0 (enExample)
MX (2) MX366728B (enExample)
PH (2) PH12015502777A1 (enExample)
RU (1) RU2666219C2 (enExample)
WO (1) WO2014209962A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2866392C2 (ru) * 2024-09-05 2026-07-20 Общество с ограниченной ответственностью "АВК" Противоаллергическое средство для собак и кошек в форме таблеток

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2016044784A1 (en) 2014-09-19 2016-03-24 Heron Therapeutics, Inc. Emulson formulations of aprepitant
RU2770050C2 (ru) * 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
KR20180118136A (ko) * 2016-02-01 2018-10-30 헤론 테라퓨틱스 인코포레이티드 Nk-1 수용체 길항제를 포함하는 에멀젼
CN109640981A (zh) * 2016-06-29 2019-04-16 曼隆治疗公司 神经激肽-1拮抗剂用于治疗多种瘙痒病症的用途
CA3073998A1 (en) * 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
SG11202003886TA (en) * 2017-11-01 2020-05-28 Nat Univ Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia
JP7324210B2 (ja) * 2018-01-31 2023-08-09 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド トファシチニブを含む局所製剤
KR20210078515A (ko) 2018-10-18 2021-06-28 아비어, 인크. 만성 신장 질환-연관 소양증의 치료 방법 및 장치
KR20220145844A (ko) 2020-02-25 2022-10-31 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
CN115015440B (zh) * 2022-07-08 2024-10-15 江苏杜瑞制药有限公司 一种生物样品中纳呋拉啡的检测方法
CN117503699A (zh) * 2023-12-08 2024-02-06 斯坦德医药研发(江苏)有限公司 阿瑞匹坦口服液制剂及制剂制造方法
WO2025250635A1 (en) * 2024-05-28 2025-12-04 Avior, Inc. Use of nalmefene hydrochloride buccal films in treating liver disease associated pruritus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030389A2 (en) * 2006-09-06 2008-03-13 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
RU2370265C1 (ru) * 2008-03-04 2009-10-20 Лев Давидович Раснецов Гель, обладающий противовоспалительным и противоаллергическим действием

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100565A1 (en) 2001-09-21 2003-05-29 Boehringer Ingelheim International Gmbh Method for the treatment or prevention of atopic dermatitis
TWI341198B (en) 2004-01-27 2011-05-01 Merck Sharp & Dohme Hydroisoindoline tachykinin receptor antagonists
CN100582093C (zh) * 2004-01-27 2010-01-20 默克公司 氢异二氢吲哚速激肽受体拮抗剂
JP2009500452A (ja) 2005-07-11 2009-01-08 メルク エンド カムパニー インコーポレーテッド ヒドロイソインドリンタキキニン受容体アンタゴニストの製造方法
WO2007044296A2 (en) 2005-10-04 2007-04-19 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2007146224A2 (en) 2006-06-12 2007-12-21 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
EP2089019A4 (en) 2006-11-02 2011-05-04 Merck Sharp & Dohme POLYMORPHIC OF A HYDROISOINDOLINE TACHYKININE RECEPTOR ANTAGONIST
EP2141992A1 (en) 2007-03-29 2010-01-13 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030389A2 (en) * 2006-09-06 2008-03-13 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
RU2370265C1 (ru) * 2008-03-04 2009-10-20 Лев Давидович Раснецов Гель, обладающий противовоспалительным и противоаллергическим действием

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SONJA STANDER et al. Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy// PLOS ONE, 2010, vol. 5, no. 6, pages e10968 - e10968, page 3 - page 4. *
TSUYOSHI OHMURA et al. Involvement of substance P in scratching behaviour in an atopic dermatitis model // EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, vol. 491, no. 2-3, pages 191 - 194. *
TSUYOSHI OHMURA et al. Involvement of substance P in scratching behaviour in an atopic dermatitis model // EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, vol. 491, no. 2-3, pages 191 - 194. SONJA STANDER et al. Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy// PLOS ONE, 2010, vol. 5, no. 6, pages e10968 - e10968, page 3 - page 4. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2866392C2 (ru) * 2024-09-05 2026-07-20 Общество с ограниченной ответственностью "АВК" Противоаллергическое средство для собак и кошек в форме таблеток
RU2866780C2 (ru) * 2024-09-05 2026-07-22 Общество с ограниченной ответственностью "АВК" Антигистаминное средство для собак и кошек в форме спрея

Also Published As

Publication number Publication date
MX2015017763A (es) 2016-06-21
BR112015031724A2 (pt) 2017-07-25
KR20160023692A (ko) 2016-03-03
JP2016523260A (ja) 2016-08-08
EP3013336A1 (en) 2016-05-04
CN105473138A (zh) 2016-04-06
CA2915474A1 (en) 2014-12-31
AU2014302694B2 (en) 2019-10-17
HK1223820A1 (zh) 2017-08-11
RU2015154037A (ru) 2017-07-28
PH12015502777A1 (en) 2016-03-21
IL243189A0 (en) 2016-02-29
PH12020500255A1 (en) 2021-02-22
MX366728B (es) 2019-07-22
WO2014209962A1 (en) 2014-12-31
MX2019008643A (es) 2019-09-10
AU2014302694A1 (en) 2016-01-07
AU2020200259A1 (en) 2020-02-06
JP2019142960A (ja) 2019-08-29

Similar Documents

Publication Publication Date Title
US10702499B2 (en) Use of NK-1 receptor antagonists in pruritus
AU2014302694B2 (en) Use of NK-1 receptor antagonist serlopitant in pruritus
US11026920B2 (en) Use of NK-1 receptor antagonist serlopitant in pruritus
KR20190039936A (ko) 다양한 소양증성 병태를 치료하기 위한 뉴로키닌-1 길항제의 용도
JP2019131594A (ja) 新規の使用
US20200121695A1 (en) Compositions and methods for treating itch, skin inflammation, and pruritus
WO2007102571A1 (ja) 機能性脳疾患治療剤
HK40007250A (zh) 神经激肽-1拮抗剂用於治疗多种瘙痒病症的用途